Back to Results

BioNexus Gene Lab Corp (BGLC)

BioNexus Gene Lab Corp is a Malaysia-based company incorporated in 2017 and listed on NASDAQ as common stock under the ticker BGLC. Through its subsidiaries, the company operates in Southeast Asia, including Malaysia, Indonesia, Vietnam, and other regional markets. Its business is organized into three segments: trading of industrial chemicals, genomic screening services, and investment holding. The trading activity focuses on chemical raw materials used in the manufacture of industrial, medical, appliance, automotive, aero, mechanical, and electronic products. The company also develops and provides non-invasive liquid biopsy tests designed for early biomarker detection.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BGLC
$2.21
40.9% Upside
Undervalued
Not available
Not available
Weak
0.0%
November 13, 2026
0.6x
1.5x
4.606 M
1.407 M
7.0%
46.5%
10.1
33.1%
Valuation • Fair Value

BioNexus Gene Lab Corp (NASDAQ-BGLC) Fair Value by Valuation Model

Review the available estimates for BioNexus Gene Lab Corp (NASDAQ-BGLC), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$2.21

Estimated upside of 40.9% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

$3.07

Discounted cash flow valuation reference.

EPV Fair Value

$2.37

Earnings power value estimate.

Comps Fair Value

$2.16

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for BioNexus Gene Lab Corp (NASDAQ-BGLC) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for BioNexus Gene Lab Corp (NASDAQ-BGLC)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

3.127 M

Current operating scale indicator.

Revenue Forecast

7.425 M

Forward revenue estimate.

EBITDA

-2.64 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review BioNexus Gene Lab Corp (NASDAQ-BGLC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for BioNexus Gene Lab Corp (NASDAQ-BGLC)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-4.59

No elevated caution signal from this screen.

Altman Z-Score

10.1

Relatively strong balance-sheet zone.

FCF / Net Income

33.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for BioNexus Gene Lab Corp (NASDAQ-BGLC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for BioNexus Gene Lab Corp (NASDAQ-BGLC)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

56

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for BioNexus Gene Lab Corp (NASDAQ-BGLC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

BioNexus Gene Lab Corp (NASDAQ-BGLC) Stock FAQ

Data-supported answers about BioNexus Gene Lab Corp (NASDAQ-BGLC), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.21
Estimated upside 40.9%
Valuation Rating
Undervalued
Estimated upside of 40.9%
Financial Health
Weak
Current financial-health read

The current fair value estimate for BioNexus Gene Lab Corp (NASDAQ-BGLC) is $2.21. This implies an estimated upside of 40.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 40.9% versus the current market price.

The current financial health read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for BioNexus Gene Lab Corp (NASDAQ-BGLC) is November 13, 2026.

The latest available data indicates no current dividend yield for BioNexus Gene Lab Corp (NASDAQ-BGLC).

The current market capitalization listed for BioNexus Gene Lab Corp is 4.606 M.

The current enterprise value listed for BioNexus Gene Lab Corp is 1.407 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for BioNexus Gene Lab Corp is NASDAQ-BGLC, and the stock is listed on NASDAQ.

BioNexus Gene Lab Corp (NASDAQ-BGLC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for BioNexus Gene Lab Corp is 7.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for BioNexus Gene Lab Corp is 46.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Trading Companies & Distributors Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

URI NYSE United Rentals Inc Fair Value Fair Market Cap 63.108 B
GWW NYSE WW Grainger Inc Fair Value Fair Market Cap 59.659 B
FAST NASDAQ Fastenal Company Fair Value Overvalued Market Cap 56.239 B
FERG NYSE Ferguson PLC Fair Value Fair Market Cap 41.482 B
SUNB NYSE Sunbelt Rentals Holdings Inc Fair Value Fair Market Cap 30.155 B
AER NYSE AerCap Holdings NV Fair Value Fair Market Cap 21.873 B
WCC NYSE WESCO International Inc Fair Value Fair Market Cap 16.771 B
WSOB NYSE Watsco B Inc Fair Value Fair Market Cap 12.035 B
WSO NYSE Watsco Inc Fair Value Fair Market Cap 12.035 B
AIT NYSE Applied Industrial Technologies Fair Value Overvalued Market Cap 11.811 B
QXO NYSE QXO Inc Fair Value Undervalued Market Cap 11.807 B
CNM NYSE Core & Main Inc Fair Value Fair Market Cap 8.119 B
MSM NYSE MSC Industrial Direct Company Inc Fair Value Fair Market Cap 6.825 B
GATX NYSE GATX Corporation Fair Value Fair Market Cap 6.28 B
RUSHA NASDAQ Rush Enterprises A Inc Fair Value Fair Market Cap 5.873 B
RUSHB NASDAQ Rush Enterprises B Inc Fair Value Overvalued Market Cap 5.873 B
XMTR NASDAQ Xometry Inc Fair Value Overvalued Market Cap 5.57 B
EQPT NASDAQ EquipmentShare Com Inc Fair Value Fair Market Cap 4.556 B
HRI NYSE Herc Holdings Inc Fair Value Fair Market Cap 4.522 B
SITE NYSE Siteone Landscape Supply Inc Fair Value Undervalued Market Cap 3.95 B